Central serous chorioretinopathy (CSC), a self-limiting disease, is one of the most common diseases of the posterior segment. Whether therapy is necessary and how to treat CSC remain disputable. Recently, progress in photodynamic therapy (PDT) once again draws the attention of domestic ophthalmologists. This article reviews changes in the understandings of CSC pathogenesis and the changes in the treatment concept, analyzes whether CSC needs therapy, and whether PDT is more effective, economically justified and safe.
赵明威. 中心性浆液性脉络膜视网膜病变的治疗观念亟待改变[J]. 中华眼视光学与视觉科学杂志, 2013, 15(1): 1-4.
ZHAO Ming-wei. Concepts about the treatment of central serous chorioretinopathy need to change. Chinese Journal of Optometry Ophthalmology and Visual Science, 2013, 15(1): 1-4. DOI: 10.3760/cma.j.issn.1674-845X.2013.01.001
Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol,2008,86:126-145.
[2]
Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol,1979, 63:674-677.
[3]
Gilbert CM, Owens SL, Smith PD, et al. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol,1984,68:815-820.
[4]
Ladas ID, Rouvas AA, Apostolopoulos M, et al. Diffuse retinal pigment epitheliopathy: treatment with laser photocoagulation. Eur J Ophthalmol,2004,14:315-320.
[5]
Ficker L, Vafidis G, While A, et al. Longterm results of treatment of central serous retinopathy—a preliminary report. Trans Ophthalmol Soc UK,1986,105:473-475.
[6]
Ficker L, Vafidis G, While A, et al. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol,1988, 72:829-834.
[7]
Gass JDM. Pathogenesis of disciform detachment of the neuroepithelium. II. Idiopathic central serous choroidopathy. Am J Ophthalmol,1967,63:587-615.
[8]
Baran NV, Gürlü VP, Esgin H. Long-term macular function in eyes with central serous chorioretinopathy. Clin Exp Ophthalmol,2005,33:369-372.
[9]
Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol,1996,114:689-692.
[10]
Castro-Correia J, Coutinho MF, Rosas V, et al. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol,1992,81:379-386.
[11]
Brancato R, Scialdone A, Pece A, et al. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch Clin Exp Ophthalmol,1987,225:166-168.
[12]
Otsuka S, Ohba N, Nakao K. A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina,2002, 22:25-32.
[13]
Jumper JM. Central serous chorioretinopathy. Br J Ophthalmol,2003,87:663.
[14]
Verma L, Sinha R, Venkatesh P, et al. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial. BMC Ophthalmol,2004,4:15-22.
Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol,2003, 87:1453-1458.
[17]
Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci,2002,43:830-841.
[18]
Barcelona PF, Luna JD, Chiabrando GA, et al. Immunohistochemical localization of low density lipoprotein receptor-related protein 1 and alpha (2)-Macroglobulin in retinal and choroidal tissue of proliferative retinopathies. Exp Eye Res,2010,91:264-272.
[19]
Schlötzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol,2002,240:748-757.
[20]
Chan WM, Lam DS, Lai TY, et al. Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am J Ophthalmol,2003, 136:836-845.
[21]
Ergun E, Tittl M, Stur M. Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy. Arch Ophthalmol,2004, 122:37-41.
[22]
Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina,2003,23:288-298.
[23]
Cardillo PF, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina ,2003,23: 752-763.
[24]
Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina,2003,23:235-237.
[25]
Ober MD, Yannuzzi LA, Do DV, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology,2005,112:2088-2094.
[26]
Chan WM, Lai TY, Lai RY et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology,2008,115:1756-1765.
[27]
Zhao MW, Zhou P, Xiao HX, et al. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dosage of verteporfin. Retina,2009,29:1155-1161.